TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer

Li, Yan; Yu, Qing; Zhang, Zhengguo; Wang, Jian; Li, Simin; Zhang, Jiangyuan; Liu, Guangwei

doi:10.18632/oncotarget.11681

Cited by 21 publications

(14 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…57 T H 2 level increases might also link AD and vitiligo, leading to their high co-occurrence. 58 Levels of IL-9, which was recently associated with AD 59 and psoriasis 60 and shown to be involved in autoimmune disorders, 61,62 were also found to be increased in our cohort of patients with vitiligo.…”

Section: Discussionsupporting

confidence: 58%

Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases

Czarnowicki

Leonard

et al. 2019

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 58%

Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases

Czarnowicki

Leonard

et al. 2019

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…The regulation of antigen-specific Th9 proliferation and differentiation was not fully elucidated. The development of Th9 cells relies on various signaling pathways ( 30 , 35 ). Several cytokines, including IL-1, IL-7, IL-21, and IL-25, were identified to synergistically promote Th9 cell development ( 30 , 36 ).…”

Section: Discussionmentioning

confidence: 99%

Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma

et al. 2021

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection induces dysfunction of immune response and chronic liver damage. However, the mechanisms that account for HBV-related hepatocellular carcinoma (HCC) are poorly understood. The aim of present study was to investigate the modulatory role of interleukin (IL)-35, an immunosuppressive cytokine, to IL-9-secreting T cells in hepatitis B-related HCC. Twenty-two HBV-related HCC patients, twenty-seven chronic hepatitis B (CHB) patients, and eleven controls were enrolled. Serum IL-35 and IL-9 concentration was measured by ELISA. Peripheral and liver-infiltrating non-specific and HBV-specific Th9 and Tc9 cells were assessed by flow cytometry. The regulatory activity of IL-35 to peripheral and liver-infiltrating Th9 cells was assessed in co-culture system between CD8+ T cells and HepG2.2.15 cells. Serum IL-35 was up-regulated, while IL-9 was down-regulated in HBV-related HCC patients compared with in CHB patients and controls. Peripheral non-specific and HBV-specific Th9 cells, but not Tc9 cells, were decreased in HBV-related HCC patients. Liver-infiltrating non-specific and HBV-specific Th9 cells were also reduced in HCC tumor sites. CD8+ T cells from CHB and HBV-related HCC patients revealed decreased cytotoxicity compared with those from controls. Autologous Th9 cells mediated the elevation of CD8+ T cell cytotoxicity, and this process was depending on IL-9 secretion. Recombinant IL-35 stimulation inhibited IL-9 secretion and PU.1 mRNA expression in non-specific and HBV-specific Th9 cells, leading to the suppression of Th9-mediated CD8+ T cell cytotoxicity in CHB and HBV-related HCC patients. Our current data indicated that IL-35 might dampen non-specific and HBV-specific Th9 cells activity in HBV-related HCC patients.

show abstract

“…Th9 cells are a subset of CD4 + T cells characterized by the secretion of IL-9, as well as IL-10 and IL-21 [ 94 ]. As Th2 cells, their differentiation is dependent on the signaling of IL-4 through STAT6, but it additionally requires the presence of TGF-β [ 95 ].…”

Section: Th9 Cellsmentioning

confidence: 99%

Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy

Andreu-Sanz

Kobold

2023

Cancers

View full text Add to dashboard Cite

Historically, CD8+ T cells have been considered the most relevant effector cells involved in the immune response against tumors and have therefore been the focus of most cancer immunotherapy approaches. However, CD4+ T cells and their secreted factors also play a crucial role in the tumor microenvironment and can orchestrate both pro- and antitumoral immune responses. Depending on the cytokine milieu to which they are exposed, CD4+ T cells can differentiate into several phenotypically different subsets with very divergent effects on tumor progression. In this review, we provide an overview of the current knowledge about the role of the different T helper subsets in the immune system, with special emphasis on their implication in antitumoral immune responses. Furthermore, we also summarize therapeutic applications of each subset and its associated cytokines in the adoptive cell therapy of cancer.

show abstract

TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer

Cited by 21 publications

References 94 publications

Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases

Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases

Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma

Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy

Contact Info

Product

Resources

About